Traffic Roots Audience Pixel

Post categorized under: Cannabis

Cannabis

With the Cannabis and agriculture industry increasingly competitive for labs, growers and processors, new innovation and improved practices can be the difference in delivering ROI and outlasting competitors. PathogenDx delivers a unique Microarray technology that dramatically reduces testing turnaround time, adds flexibility to how and what can be tested for, and increases efficiencies for a cleaner Cannabis future. Here are the issues Cannabis faces now, with insights to help us all compete and win.


  • Two-thirds of California marijuana labs can’t test flower after rule change

    Less than one-third of California’s 37 licensed cannabis testing laboratories began the new year permitted to test marijuana flower and non-infused pre-rolls. Only 12 labs are currently compliant with a recent state law imposing standardized methods to test for THC potency.

    Read more »

  • Mississippi to rescind medical marijuana lab’s testing license

    The Mississippi health department plans to revoke the medical marijuana testing license belonging to Natchez-based Rapid Analytics. The agency said its investigation revealed that Rapid Analytics had engaged in “significant deviations from regulatory standards and approved procedures.”

    Read more »

  • Florida bill that bans delta-8, other compounds sent to governor

    The legislator pushback against delta-8 continues. The measure to ban hemp-derived products containing delta-8 and delta-10 THC was unanimously approved by the Senate in February. Florida voters are due to decide on adult-use legalization in November.

    Read more »

  • Olympia cannabis testing lab license suspended

    Washington Liquor and Cannabis Board has suspended the certification of an Olympia cannabis testing lab. The True Northwest lab received an emergency suspension of its state certification on Tuesday and has 180 days to appeal that decision to the Cannabis Board.

    The agency’s staff determined that the lab failed to meet several accreditation requirements, including not having a lab director and not having its scales properly calibrated. The lab provided incorrect results to its customers, the Board said.

    Read more »

  • Hop Latent Viroid: Alarms over global spread of dangerous marijuana viroid

    The dangerous and infectious hop latent viroid that’s been on the radar of many cannabis growers since its discovery in 2018 has spread beyond North America and is threatening to spiral out of control and cause billions of dollars in industry losses, experts are warning. Researchers are calling the viroid – which is surfacing across the world – “a hidden threat” and the “biggest concern for cannabis and hop growers worldwide.”

    The only surefire way to detect Hop Latent Viroid and similar viroids harming your cannabis grow is through accurate molecular testing like PathogenDx.

    Read more »

  • Cannabis testing lab analysis finds routine THC inflation, data manipulation

    The THC potency of marijuana flower sold in legal stores in four states is routinely and systematically inflated, sometimes by as much as 25% or more, according to an independent analysis of licensed cannabis testing lab data. The analysis suggests tainted products that should have been failed for contaminants and destroyed or remediated instead was passed and eventually sold by legal retailers. In addition, confirmation that THC potency inflation is running rampant – and often unchecked – across legal U.S. marijuana markets also stands to undermine consumer confidence in product labeling.

    Read more »

  • FDA Sends Warnings To Food Firms Selling CBD

    A food firm in Nevada is on notice from the FDA for concern that some of the firm’s CBD products are in forms that are appealing to children. The FDA’s review brought concern, that with these products, there is a risk of unintended consumption of the CBD ingredient by consumers. Because of the following issues, the FDA determined that introducing or delivering these products for introduction into interstate commerce violates the FD&C Act.

    Read more »

  • Cannabis Regulatory Compliance Is Well Worth The Cost

    While in many ways it still feels like an entirely new frontier, widespread cannabis legalization in the United States began more than a full decade ago. In the time since, it has evolved into one of the fastest growing and most robust industries in the United States, generating billions of dollars in sales each year. In the states where it’s legal, it is also one of the most heavily regulated industries.

    Read more »

  • What’s In Illicit New York Cannabis

    Some New York Cannabis products sold at unlicensed storefronts are not only illegal, but also contaminated with harmful bacteria, heavy metals and toxic pesticides, according to an industry report released last week. A medical Cannabis trade group found contaminants such as E. coli and salmonella in some products purchased at these unlicensed dispensaries.

    Read more »

  • Has the CBD Regulatory Landscape Changed?

    The regulation of CBD in the United States can be described as makeshift, and that is being generous. On a federal level, Cannabis in all shapes and forms is a Schedule I controlled substance, but no federal agency has taken charge of regulating CBD products, leaving decisions up to the individual states.

    Read more »